# Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

> **NCT06085079** · PHASE4 · UNKNOWN · sponsor: **Massachusetts Eye Research and Surgery Institution** · enrollment: 20 (estimated)

## Conditions studied

- Uveitis, Posterior
- Uveitis, Anterior
- Uveitis, Intermediate
- Panuveitis

## Interventions

- **DRUG:** Ixekizumab Prefilled Syringe

## Key facts

- **NCT ID:** NCT06085079
- **Lead sponsor:** Massachusetts Eye Research and Surgery Institution
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085079, "Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06085079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*